SPCs Clause Samples

The SPCs (Special Purpose Companies) clause defines the role and use of entities created specifically for a particular transaction or project. Typically, this clause outlines the requirements for establishing an SPC, such as its legal structure, ownership, and operational limitations, and may specify how the SPC will interact with other parties in the agreement. By clearly delineating the function and boundaries of SPCs, this clause helps isolate financial risk, protect parent companies from liabilities, and ensure that obligations are met solely by the designated entity.
SPCs. Notwithstanding anything to the contrary contain herein, any Bank except the Agent, (a “Granting Bank”) may grant to a special purpose funding vehicle (an “SPC”) the option to fund all or any part of any Loan that such Granting Bank would otherwise be obligated to fund pursuant to this Agreement; provided, that (i) nothing herein shall constitute a commitment by any SPC to fund any Loan, (ii) if an SPC elects not to exercise such option or otherwise fails to fund all or any part of such Loan, the Granting Bank shall be obligated to fund such Loan pursuant to the terms hereof, (iii) no SPC shall have any voting rights pursuant to Section 11.1 (all such voting rights shall be retained by the Granting Bank) and (iv) with respect to notices, payments and other matters hereunder, the Company, the Agent and the Banks shall not be obligated to deal with an SPC, but may limit their communications and other dealings relevant to such SPC to the applicable Granting Bank. The funding of a Loan by an SPC hereunder shall utilize the Commitment of the Granting Bank to the same extent that, and as if, such Loan were funded by such Granting Bank. Each party hereto hereby agrees that no SPC shall be liable for any indemnity or payment under this Agreement for which a Lender would otherwise be liable for so long as, and to the extent, the Granting Bank provides such indemnity or makes such payment. In furtherance of the foregoing, each party hereto hereby agrees (which agreements shall survive termination of this Agreement) that, prior to the date that is one year and one day after the payment in full of all outstanding commercial paper or other senior indebtedness of any SPC, it will not institute against, or join any other Person in instituting against, such SPC any bankruptcy, reorganization, arrangement, insolvency or liquidation proceedings under the laws of the United States or any state thereof. Notwithstanding anything to the contrary contained in this Agreement, any SPC may disclose on a confidential basis any non-public information relating to its funding of Loans to any rating agency, commercial paper dealer or provider of any surety or guarantee to such SPC. The grant of an option pursuant to this Section shall not be deemed either an assignment or a participation pursuant to Section 11.16 or 11.17, respectively, and shall not reduce the Commitment of the Granting Bank. This Section 11.21 may not be amended without the prior written consent of each Granting Bank,...
SPCs. At GSK’s request and expense, Unigene shall seek to obtain SPCs based on Unigene Patent Rights or authorize GSK to obtain SPCs based on Unigene Patent Rights on Unigene’s behalf where GSK holds an NDA or MAA, GSK shall at its sole discretion provide to Unigene a copy of said NDA or MAA and any information necessary for the purpose of obtaining an SPC based on a Unigene Patent Right.
SPCs. Notwithstanding anything to the contrary contained herein, any Lender (a “Granting Lender”) may grant to a special purpose funding vehicle identified as such in writing from time to time by the Granting Lender to the Administrative Agent and the Borrower (an “SPC”) the option to provide all or any part of any Loan that such Granting Lender would otherwise be obligated to make pursuant to this Agreement; provided that (i) nothing herein shall constitute a commitment by any SPC to fund any Loan and (ii) if an SPC elects not to exercise such option or otherwise fails to make all or any part of such Loan, the Granting Lender shall be obligated to make such Loan pursuant to the terms hereof. Each party hereto hereby agrees that (i) neither the grant to any SPC nor the exercise by any SPC of such option shall increase the costs or expenses or otherwise increase or change the obligations of the Borrower under this Agreement (including its obligations under Section 3.01 or 3.02), (ii) no SPC shall be liable for any indemnity or similar payment obligation under this Agreement for which a Lender would be liable and such liability shall remain with the Granting Lender, and
SPCs. Notwithstanding anything to the contrary contained herein, any Lender (a “Granting Lender”) may grant to a special purpose funding vehicle (an “SPC”), identified as such in writing from time to time by the Granting Lender to the Administrative Agent and the Borrower the option to fund all or any part of any Advance that such Granting Lender would otherwise be obligated to fund pursuant to this Agreement; provided, that (i) nothing herein shall constitute a commitment by any SPC to fund any Advance, (ii) if an SPC elects not to exercise such option or otherwise fails to fund all or any part of such Advance, the Granting Lender shall be obligated to fund such Advance pursuant to the terms hereof and (iii) the Borrower may bring any proceeding against the Granting Lender or the SPC in order to enforce any rights of the Borrower hereunder.
SPCs. Notwithstanding anything to the contrary contained herein, any Lender (a "Granting Lender") may grant to a special purpose funding vehicle (an "SPC") the option to fund all or any part of any Loan that such Granting Lender would otherwise be obligated to fund pursuant to this Credit Agreement; provided that (i) nothing herein shall constitute a commitment by any SPC to fund any Loan, (ii) if an SPC elects not to exercise such option or otherwise fails to fund all or any part of such Loan, the Granting Lender shall be obligated to fund such Loan pursuant to the terms hereof, (iii) no SPC shall have any voting rights pursuant to Section 11.6 (all such voting rights shall be retained by the Granting Lenders), <PAGE>
SPCs. S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇▇ (SPC) Obinutuzumab (Gazyva) SZ 55/2014 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇▇ (SPC) Obinutuzumab (Gazyva) 2014C/059 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇▇▇▇▇▇ (SPC) Obinutuzumab (Gazyva) 17-Sep-14 0 939 127 Pending S101258DE53-1 Germany (SPC) Obinutuzumab (Gazyva) ############# 17-Sep-14 0 939 127 Pending S101258ES53-1 Spain (SPC) Obinutuzumab (Gazyva) C201430064 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇ (SPC) Obinutuzumab (Gazyva) 14 C 0070 17-Sep-14 0 939 1▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ (SPC) Obinutuzumab (Gazyva) SPC/GB14/065 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇ (SPC) Obinutuzumab (Gazyva) UB2014P001407 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇▇▇▇▇▇ (SPC) Obinutuzumab (Gazyva) 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇ (SPC) Obinutuzumab (Gazyva) 1490058-3 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇▇ (SPC) Generic SPC Based on Tysabri SZ 54/2014 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇▇ (SPC) Generic SPC Based on Tysabri 2014C/060 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇▇▇▇▇▇ (SPC) Generic SPC Based on Tysabri 17-Sep-14 0 939 127 Pending S101258DE53-2 Germany (SPC) Generic SPC Based on Tysabri ############# 17-Sep-14 0 939 127 Pending S101258ES53-2 Spain (SPC) Generic SPC Based on Tysabri C201430065 17-Sep-14 0 939 127 Pending S101258FR53-2 France (SPC) Generic SPC Based on Tysabri 14 C 0071 17-Sep-14 0 939 1▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ (SPC) Generic SPC Based on Tysabri SPC/GB14/066 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇ (SPC) Generic SPC Based on Tysabri UB2014P001408 17-Sep-14 0 939 127 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇▇▇▇▇▇ (SPC) Generic SPC Based on Tysabri 17-Sep-14 0 939 127 Pending S101258SE53-2 Sweden (SPC) Generic SPC Based on Tysabri 1490059-1 17-Sep-14 0 939 127 Pending
SPCs. Roche shall cooperate with BPM in gaining patent term restorations, extensions and/or SPCs wherever applicable to such Patent Rights within Collaboration Compound IP and Other Compound IP and Patent Rights [***] related to each of the Reversion Products.
SPCs. S101258DE55-1 Germany (SPC) Pertuzumab (Perjeta) ############# 30-Apr-14 1 491 556 Pending S101258ES55-1 Spain (SPC) Pertuzumab (Perjeta) C201430029 30-Apr-14 1 491 556 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇▇ (SPC) Pertuzumab (Perjeta) 14 C 0035 30-Apr-14 1 491 556 Pending S101258GB55-1 United Kingdom (SPC) Pertuzumab (Perjeta) SPC/GB14/035 30-Apr-14 1 491 556 Pending S▇▇▇▇▇▇▇▇▇▇-▇ ▇▇▇▇▇ (SPC) Pertuzumab (Perjeta) UB2014CCP1.376 30-Apr-14 1 491 556 1376 5-Aug-14 Granted 28-Dec-14 S101258GB55-2 United Kingdom (SPC) Generic SPC based on Tocilizumab (RoActemra) SPC/GB14/036 30-Apr-14 1 491 556 Pending S101258DE06 Germany (SPC) Natalizumab or pharmaceutically acceptable salts thereof 12 2006 000 036.4 7-Aug-06 68925536.5 Pending S101258DE07 Germany (SPC) Ranibizumab or Pharmaceutically Acceptable Salts Thereof 12 2007 000 037.5 11-Apr-07 68925536.5 Pending S101258GB02 United Kingdom (SPC) Palivizumab or its pharmaceutically acceptable salts SPC/GB00/007 11-Feb-00 GB0451216 SPC/GB00/007 8-Mar-02 Granted 12-Aug-14 S101258GB03 United Kingdom (SPC) Trastuzumab or pharmaceutically acceptable salts thereof SPC/GB00/032 29-Nov-00 GB0451216 SPC/GB00/032 30-Sep-05 Granted 28-Jul-14 S101258GB04 United Kingdom (SPC) Bevacizumab or pharmaceutically acceptable salts thereof SPC/GB05/009 17-Feb-05 GB0451216 SPC/GB05/009 9-Aug-05 Granted 27-Dec-14 S101258GB05 United Kingdom (SPC) Omalizumab or pharmaceutically acceptable salts thereof SPC/GB05/052 8-Dec-05 GB0451216 SPC/GB05/052 14-Aug-08 Granted 27-Dec-14 S101258GB06 United Kingdom (SPC) Natalizumab or pharmaceutically acceptable salts thereof SPC/GB06/027 7-Aug-06 GB0451216 SPC/GB06/027 1▇-▇▇▇-▇▇ ▇▇▇▇▇▇▇ ▇▇-▇▇▇-▇▇ ▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ (SPC) Ranibizumab or Pharmaceutically Acceptable Salts Thereof SPC/GB07/033 17-Apr-07 GB0451216 SPC/GB07/033 4-Oct-09 Granted 27-Dec-14 S101258PT07 Portugal (SPC) Ranibizumab or Pharmaceutically Acceptable Salts Thereof 10724 16-Apr-07 PT92758 269 11-Mar-13 Granted 20-Oct-15 73447/010400AT Austria ZENAPAX® (Daclizumab) Granted E133452 12/28/2009 SZ32/99 8/24/1999 SZ32/99 8/31/2001 3/3/2013 Expired 73447/010400AU Australia ZENAPAX® (Daclizumab) Granted 647383 12/28/2009 51532/90 12/3/1999 647383 5/24/2000 9/16/2014 Expired 73447/010400BE Belgium ZENAPAX® (Daclizumab) Granted EP0451216 12/28/2009 099C0028 7/19/1999 099C0028 10/5/1999 3/3/2013 Expired 73447/010400DE Germany ZENAPAX® (Daclizumab) Granted 68925536.5 12/29/2009 2E+07 6/30/1999 19975047 1/8/2008 3/3/2013 Expired 73447/010400DK Denmark ZE...